These primarily included tyrosine kinase inhibitors (TKI) against the epithelial growth receptor (EGFR), such as gefitinib and erlotinib, which successfully counteract tumour progression in NSCLC patients harbouring genetic alterations of EGFR4. Here, EGFR is linked to non-small cell lung carcinoma.